- Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancers. Cancer 1980; 46: 2884-8.
- Leake R. Receptors and response to endocrine therapy. Rev Endocrine Related Cancer 1987; 20: 45-9.
- Biswas DK, Averboukh L, Sheng S, et al. Classification of breast cancer cells on the basis of a functional assay for estrogen receptor. Md Med 1998; 4: 454-67.
- Poulsom R, Hariby AM, Lalani EN, et al. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol 1997; 183: 30-8.
- May FEB, Westley BR. Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells. Cancer Res 1986; 46: 6034-40.
- Berry M, Nunez AM, Chambon P. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sd USA 1989; 64: 1218-22.
- Fulco RA, Petix M, Salimbeni V, Tone EA. Prognostic significance of the estrogen-regulated proteins, cathepsin-D and pS2, in breast cancer. Minerva Med 1998; 89: 5-10.
- Balleine RL, Clarke CL. Expression of the oestrogen responsive protein pS2 in human breast cancer. Histol Histopathol 1999; 14: 571-8.
- Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histdogical grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
- Looi LM, Yap SF, Cheah PL. Correlation between oestrogen receptor protein expression in infiltrating ductal carcinoma of breast by immunohistochemistry and cytosol measurements. Ann Acad Med Singapore 1997; 26: 750-3.
- Motomura K, Koyama H, Noguchi S, et al. Effect of tamoxifen on pS2 expression in human breast cancers. Oncology 1997; 54: 424-8.
- loakim-Liossi A, Karakitsos P, Markopoulos C, et al. Expression of pS2 protein and estrogen and progesterone receptor status in breast cancer. Acta Cytol 1997; 41: 713-6.
- Ahr A, Schorl A, Gohring UJ, et al. Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay. Pathologe 1995; 16: 278-84.
- Horiguchi J, lino Y, Takei H. Expression of pS2 estrogen-inducible protein in primary breast cancer. Oncology 1996; 53: 12-5.
- Luqmani Y, Temmim L, Memon A, et al. Immunoradiometric measurement of pS2 in breast cancer - correlation with steroid receptors and plasminogen activators. Acta Oncol 1999; 38: 805-14.
- Brown AMC, Jeltsh JM, Roberts M, Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sei USA 1984; 81: 6344-8.
- Kida N, Yoshimura T, Mori K, Hayashi K. Hormonal regulation of synthesis and secretion of pS2 protein relevant to growth of human breast cancer cells (MCF-T). Cancer Res 1989; 49: 3494-8.
- Spyratos F, Andrieu C, Hacene K, et al. pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 1994; 69: 394-7.
- Foekens JA, Portengen H, Look MP, et al. Relationship of pS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 1994; 70: 1217-23.
- Thompson AM, Elton RA, Hawkins RA, Chetty U, Steel CM. PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer. Br J Cancer 1998; 77: 492-6.
- Schwartz LH, Koerner FC, Edgerton SM, et al. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 1991; 51: 624-8.
- Soubeyran I, Quenel N, Coindre JM, et al. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in postmenopausal breast cancer patients. Br J Cancer 1996; 74: 1120-5.
- Nunez AM, Berry M, Imler JL, Chambon P. The 5' flanking region of the pS2 gene contains a complex enhancer region responsive to estrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J 1989; 8: 823-9.
- May FEB, Westley BR. Trefoil proteins: Their role in normal and malignant cells. (Review.) / Pathol 1997; 183: 4-7.
- Miyashita S, Hirota M, Yamamoto T, et al. Effect of basic fibroblast growth factor on synthesis/secretion of pS2 protein by human breast cancer cells (MCF-T). Eur J Biochem 1994; 225: 1041-6.
- Cappelletti V, Fioravanti L, Miodini P, Di Fronzo G. Modulation of cathepsin-D and pS2 protein levels in human breast cancer cell lines. Tumour Biol 1996; 17: 290-8.
- Jakowlew SB, Breathnach R, Jeltsch JM, Masiakowski P, Chambon P. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer line MCF-7. Nucleic Acids Res 1984; 2861-78.
- Mori K, Fujii R, Kida N, et al. Complete primary structure of human estrogen responsive gene (pS2) product. J Biochem 1990; 107: 73-6.
- Giamarchi C, SolanasM, Chailleux C, et al. Chromatin structure of the regulatory regions of pS2 and cathepsin D genes in hormonedependent and -independent breast cancer cell lines. Oncogene 1999; 18:533-41.
- Tong D, Schneeberger C, Czerwenka K, et al. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcriptionpdymerase chain reaction in human breast cancer. Clin Cancer Res 1999; 5: 1497-502.
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research